COVID Vaccine ‘Miracle’ May Set Unrealistic Expectations For US Supply Chains
The story of the US coronavirus vaccine production ramp-up is putting the drug industry in an extraordinarily favorable public relations position. One downside, however, may be complicating the industry’s message about the limits of ‘Buy American’ efforts on pharmaceutical supply chains overall.
You may also be interested in...
Biden Administration seeks to put its stamp on a new phase of the US government’s collaboration with the pharma industry against COVID-19.
Most US agencies can expect relatively friendly oversight from a Democratic Congress. The US FDA might be one exception, as a recent House hearing on foreign inspections shows.
President Biden’s relationship with the US pharmaceutical industry is starting out with the starkest contrast imaginable with the initial approach of the Trump Administration – at least on the symbolic level.